We work closely with industry partners at every stage of amyloidosis therapeutic development to advance the most promising ideas and accelerate the development of breakthrough treatments to get products to market faster.
We are committed to fostering critical collaborations with companies to support promising programs. Our unique relationships provide access to all stakeholders including research and clinical experts, patients, regulators and payers across the globe.
We partner with companies that wish to benefit from our unbiased expertise and extensive knowledge of the field to accelerate shared research goals to improve outcomes and quality of life for patients. We provide strategic consultation and develop partnerships across a number of different areas, both on individual and multi-company levels.
The following overview provides example opportunities for how industry can partner, contribute, and support ARC’s impact.
In 2021, ARC launched the ASPIRE: Amyloidosis Industry Collaborative. ASPIRE convenes amyloidosis industry partners in the pre-competitive space to address some of the most urgent issues faced by the amyloidosis community. As a Collaborative, we define a framework for collective impact, establish a shared priority agenda, and partner with clinical, research, policy, regulatory, non-profit, and patient representatives to advance the amyloidosis field. ASPIRE aims to accelerate progress in the areas of diagnosis, care, and health disparities through collaborative project designs and the subsidization of cooperative solutions.
Learn more here
Our corporate partners provide critical contributions that support the development and dissemination of educational resources. Our resource booklets, ARC Talks webinar series, and accredited continuing medical education programs help to engage and bridge the community while providing opportunities for capacity-building and training for the next generation of amyloidosis experts.
ARC’s My Amyloidosis Pathfinder (MAP) is a proprietary clinical trial matching tool designed to educate amyloidosis patients to take part in trials and find amyloidosis treatment centers. MAP generates customized notifications to let patients know when research opportunities arise or when they meet eligibility criteria for clinical trials. The data collected in MAP provides insights on trial-ready patients which can help inform the design of more effective clinical trials and identify target populations for study recruitment. MAP is a tool that can be leveraged for data collection, trial dissemination, and participant recruitment.
View My Amyloidosis Pathfinder here
In 2018 ARC hosted a Research Roundtable. This workshop meeting convened amyloidosis experts from basic and translational research, academia, clinical practice, industry, and regulatory bodies. The purpose of the workshop was to define the most critical and field shaping research questions in systemic amyloidosis. Following the workshop, we published a white paper; Advancing Amyloidosis: A Research Roadmap with recommendations and a blueprint for areas of research best positioned to accelerate progress and make significant, meaningful contributions to patient outcomes.
On November 16, 2015, at the recommendation of the US Food and Drug Administration (FDA), the Amyloidosis Research Consortium (ARC) hosted an externally-led Patient-Focused Drug Development meeting to share with the Agency and other stakeholders, including industry, the experiences of people living with systemic amyloidosis, the impact on daily life, and perspectives on approaches to treating amyloidosis. The meeting was conducted in accordance with the Agency’s Patient-Focused Drug Development (PFDD) initiative, an FDA commitment under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), to systematically gather patients’ perspectives on their condition and available therapies to treat their condition.